1.34

0.00% 0.00

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $1.34, with a volume of 58,146. It is up +0.00% in the last 24 hours and up +1,247% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$1.34

Open:

$1.35

24h Volume:

58,146

Relative Volume:

0.01

Market Cap:

$3.46M

Revenue:

Net Income/Loss:

$-25.09M

P/E Ratio:

-0.2586

EPS:

-5.1824

Net Cash Flow:

$-18.40M

1W Performance:

-15.72%

1M Performance:

+1,247%

6M Performance:

+69.62%

1Y Performance:

-21.18%

1-Day Range:

$1.31

$1.41

1-Week Range:

$1.25

$1.58

52-Week Range:

$0.095

$1.93

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

CLDI's Discussions on Twitter

Compare CLDI vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDI Calidi Biotherapeutics Inc	1.34	3.46M	0	-25.09M	-18.40M	-5.1824
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-23	Initiated	H.C. Wainwright	Buy
Oct-09-23	Initiated	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

Aug 20, 2026

ARMISTICE CAPITAL, LLC Slashes Calidi Biotherapeutics (CLDI) Sta - GuruFocus

Aug 20, 2026

Aug 19, 2026

Calidi Biotherapeutics (CLDI) grants director 5,000 options - Stock Titan

Aug 19, 2026

Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) CEO awarded 32K options vesting over 4 years - Stock Titan

Aug 19, 2026

Aug 18, 2026

Calidi (CLDI) Report Card: The EPS Result Is Above Expectation in the Current Update; Reaction Snapshot: Shares Close 6.62% Lower in the Latest SessionTrough Earnings Signal - vinanet.vn

Aug 18, 2026

Calidi (CLDI) Closing Snapshot: Retreats 5.59% to $1.28 in the Current Update; Technical Position: the Near-Term Reference Band Stretches From $1.22 to $1.34 on the DayCalendar Spread Trade - vinanet.vn

Aug 18, 2026

Aug 17, 2026

Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire

Aug 17, 2026

Aug 14, 2026

Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan

Aug 14, 2026